Abzena plc company

Abzena (AIM: ABZA) provides proprietary technologies and complementary services to enable the development and manufacture of biopharmaceutical products, a growing area that requires specialist knowledge and expertise. The Group has a global customer base which includes the majority of the top 20 biopharmaceutical companies as well as large and small biotech companies and academic groups. The term “Abzena inside” is used by Abzena to describe products that have been created using its proprietary technologies and are being developed by its partners, and include Composite Human Antibodies™ and ThioBridge™ Antibody Drug Conjugates (ADCs). Abzena has the potential to earn future licence fees, milestone payments and/or royalties on “Abzena inside” products.

Investors

Headquarters: Cambridge, Cambridgeshire, United Kingdom
Funding Status: IPO
Employee Number: 101-250
Investment Stage: N/A
Number Of Exists: N/A
Technology: P4 Medicine
Investor Type: Company
Founded Date: 2002
Industry: Personalized Medicine
Register and Claim Ownership